Author:
Dobesh Paul P.,Fermann Gregory J.,Christoph Mary J.,Koch Bruce,Lesén Eva,Chen Hungta,Lovelace Belinda,Dettling Theresa,Danese Mark,Ulloa Julie,Danese Sherry,Coleman Craig I.
Funder
AstraZeneca
AstraZeneca Gothenburg
National Institutes of Health
Siemens USA
Patient-Centered Outcomes Research Institute
Reference7 articles.
1. Letter to Dobesh et al on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding;Lucarelli;Res Pract Thromb Haemost,2024
2. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study;Dobesh;Res Pract Thromb Haemost,2023
3. White CM, Caroti KS, Bessada Y, Baker WL, Hernandez AV, Dobesh P, et al. High risk of bias in studies assessing reversal and replacement agents for factor Xa inhibitor bleeding. Presented at: European Emergency Medicine Congress (EUSEM) 2023, 17-20 September 2023, Barcelona, Spain.
4. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage;Connolly;N Engl J Med,2024
5. Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants;Ip;JAMA Netw Open,2024